AI Article Synopsis
- Stroke is a major cause of death and disability, but only a small fraction of patients receive treatment due to the limited time available for intervention and lengthy evaluation processes.
- Researchers are exploring blood-based nucleic acid biomarkers to improve stroke diagnosis, with a focus on mRNA markers from circulating leukocytes.
- A new point-of-care technology is being developed to quickly detect multiple mRNA molecules in the blood, aiming to streamline stroke treatment.
Article Abstract
Stroke is a leading cause of death and disability in adults, but at present, treatment for ischemic stroke reaches only a small percentage of patients. This is because of the very short time window for treatment and the time-consuming evaluation involved. Intense efforts are underway to find novel approaches to expedite stroke diagnosis and treatment. In this review, we provide the rationale for the use of blood-based nucleic acid biomarkers to advance stroke diagnosis. We describe mRNA markers identified in genomic profiling of circulating leukocytes and then outline technological issues involved in the application of these results. We then describe the novel point-of-care technology that is in development for the rapid detection of multiple mRNA molecules in circulating leukocytes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737159.2015.1024660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!